Arcus Biosciences Announces New Employee Stock Options and Restricted Stock Units Under 2020 Inducement Plan
Arcus Biosciences Inc., a global biopharmaceutical company, has announced new employment inducement grants. The company's Compensation Committee has granted stock options to two new employees, allowing them to purchase a total of 8,400 shares of the company's common stock at an exercise price of $9.85 per share, reflecting the closing price on June 9, 2025. Additionally, the employees were awarded restricted stock units for a total of 4,200 shares. These equity awards were issued under the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020, in accordance with NYSE rules.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610907109) on June 10, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。